Page last updated: 2024-08-23

diltiazem and rivaroxaban

diltiazem has been researched along with rivaroxaban in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Becker, RC; Berkowitz, SD; Breithardt, G; Fox, KAA; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Washam, JB	1
Barnes, GD; Bartlett, JW; Ha, NB; Kuo, L; Mouland, E; Renner, E	1

Trials

1 trial(s) available for diltiazem and rivaroxaban

Article	Year
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). The American journal of cardiology, 2017, Aug-15, Volume: 120, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Verapamil; Warfarin	2017

Article

Year

Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).

The American journal of cardiology, 2017, Aug-15, Volume: 120, Issue:4

Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Humans; Male; Risk Factors; Rivaroxaban; Stroke; Treatment Outcome; Verapamil; Warfarin

2017

Other Studies

2 other study(ies) available for diltiazem and rivaroxaban

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. The Annals of pharmacotherapy, 2019, Volume: 53, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Factor Xa Inhibitors; Female; Humans; Male; Retrospective Studies; Rivaroxaban; Treatment Outcome	2019

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013

Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem.

The Annals of pharmacotherapy, 2019, Volume: 53, Issue:1

Topics: Aged; Anticoagulants; Atrial Fibrillation; Calcium Channel Blockers; Diltiazem; Factor Xa Inhibitors; Female; Humans; Male; Retrospective Studies; Rivaroxaban; Treatment Outcome

2019